Back to Journals » ClinicoEconomics and Outcomes Research » Volume 3
ClinicoEconomics and Outcomes Research
ISSN: 1178-6981
- View all (875)
- Volume 16, 2024 (28)
- Volume 15, 2023 (67)
- Volume 14, 2022 (61)
- Volume 13, 2021 (90)
- Volume 12, 2020 (70)
- Volume 11, 2019 (71)
- Volume 10, 2018 (77)
- Volume 9, 2017 (77)
- Volume 8, 2016 (73)
- Volume 7, 2015 (64)
- Volume 6, 2014 (53)
- Volume 5, 2013 (59)
- Volume 4, 2012 (41)
- Volume 3, 2011 (19)
- Volume 2, 2010 (16)
- Volume 1, 2009 (9)
Archive: Volume 3, 2011
Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran
Rasekh HR, Imani A, Karimi M, Golestani M
ClinicoEconomics and Outcomes Research 2011, 3:207-212
Published Date: 23 November 2011
Cost-effectiveness analysis of initial HIV treatment under Italian guidelines
Colombo GL, Colangeli V, Di Biagio A, Di Matteo S, Viscoli C, Viale P
ClinicoEconomics and Outcomes Research 2011, 3:197-205
Published Date: 31 October 2011
Impact of early intervention and disease modification in patients with predementia Alzheimer’s disease: a Markov model simulation
Budd D, Burns LC, Guo Z, L’Italien G, Lapuerta P
ClinicoEconomics and Outcomes Research 2011, 3:189-195
Published Date: 7 October 2011
Corrigendum
Zoellner Y, Balp MM, Gili Marco A
ClinicoEconomics and Outcomes Research 2011, 3:187-188
Published Date: 6 September 2011
Role of centralized review processes for making reimbursement decisions on new health technologies in Europe
Stafinski T, Menon D, Davis C, McCabe C
ClinicoEconomics and Outcomes Research 2011, 3:117-186
Published Date: 30 August 2011
The role of galenic innovation in improving treatment compliance and persistence: three case studies
Zoellner Y, Balp MM, Gili Marco A
ClinicoEconomics and Outcomes Research 2011, 3:109-116
Published Date: 4 August 2011
Retrospective drug utilization review: impact of pharmacist interventions on physician prescribing
Angalakuditi M, Gomes J
ClinicoEconomics and Outcomes Research 2011, 3:105-108
Published Date: 27 June 2011
Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application
Goeree R, He J, O'Reilly D, Tarride J-E, Xie F, Lim M, Burke N
ClinicoEconomics and Outcomes Research 2011, 3:89-104
Published Date: 2 June 2011
Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy
Peng X, Ascher-Svanum H, Faries DE, Stauffer VL, Kollack-Walker S, Kinon BJ, Kane JM
ClinicoEconomics and Outcomes Research 2011, 3:79-87
Published Date: 20 April 2011
The economic burden of TNFα inhibitors and other biologic treatments in Norway
Jan Norum, Wenche Koldingsnes, Torfinn Aanes, et al
ClinicoEconomics and Outcomes Research 2011, 3:73-78
Published Date: 21 March 2011
Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder
Xianchen Liu, Yi Chen, Douglas E Faries, et al
ClinicoEconomics and Outcomes Research 2011, 3:63-72
Published Date: 15 March 2011
Cost–utility analysis of prophylaxis versus treatment on demand in severe hemophilia A
Giorgio L Colombo, Sergio Di Matteo, Maria Elisa Mancuso, et al
ClinicoEconomics and Outcomes Research 2011, 3:55-61
Published Date: 14 March 2011
Adherence to antihypertensive medications and health outcomes among newly treated hypertensive patients
Luca Degli Esposti, Stefania Saragoni, Silvia Benemei, et al
ClinicoEconomics and Outcomes Research 2011, 3:47-54
Published Date: 7 March 2011
A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy
Giorgio L Colombo, Giovanni B Gaeta, Mauro Viganò, et al
ClinicoEconomics and Outcomes Research 2011, 3:37-46
Published Date: 15 February 2011
Biosimilar medicines and cost-effectiveness
Steven Simoens
ClinicoEconomics and Outcomes Research 2011, 3:29-36
Published Date: 10 February 2011
Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy
Gerald HJ Mickisch, Björn Schwander, Bernard Escudier, et al
ClinicoEconomics and Outcomes Research 2011, 3:19-27
Published Date: 25 January 2011
The costs of hospitalization in patients with acute exacerbation of chronic obstructive pulmonary disease
Sevket Ozkaya, Serhat Findik, Atilla Guven Atici
ClinicoEconomics and Outcomes Research 2011, 3:15-18
Published Date: 17 January 2011
Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia
Xiaomei Peng, Haya Ascher-Svanum, Douglas Faries et al
ClinicoEconomics and Outcomes Research 2011, 3:9-14
Published Date: 11 January 2011
The cost-effectiveness of venous-converted acid-base and blood gas status in pulmonary medical departments
Lars Oddershede, Sabrina Storgaard Petersen, Asgerd Krogh Kristensen, et al
ClinicoEconomics and Outcomes Research 2011, 3:1-7
Published Date: 16 December 2010